Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 14, 2018
Date of report (date of earliest event reported)
MusclePharm Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Nevada
|
|
000-53166
|
|
77-0664193
|
|
(State or other jurisdictions of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Nos.)
|
4400 Vanowen St., Burbank, CA 91505
(Address of principal executive offices) (Zip
Code)
(800) 292-3909
(Registrant’s telephone number, including area
code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrants
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities
Act of 1933 (230.405 of this chapter) or Rule 12b-2of the
Securities Exchange Act of 1934 (§ 240 12b-2 of this
chapter).
Emerging
Growth Company ☐
If an
emerging growth company, indicate by a check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results
of Operations and Financial Condition.
On
August 14, 2018, MusclePharm Corporation issued a press release
announcing its financial results for the quarter ended June 30,
2018. A copy of the press release is furnished hereto as Exhibit
99.1.
The
information contained in this Current Report on Form 8-K, including
the exhibit attached hereto, is being furnished and shall not be
deemed to be “filed” for any purpose, and shall not be
deemed incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Securities Exchange Act
of 1934, as amended, regardless of general incorporation language
in any such filing.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
Press
release issued by MusclePharm Corporation, dated August 14, 2018,
announcing financial results.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
MUSCLEPHARM
CORPORATION
|
|
|
|
|
|
|
|
Date: August 14,
2018
|
By:
|
/s/ Ryan
Drexler
|
|
|
|
Name:
|
Ryan
Drexler
|
|
|
|
Title:
|
Chief Executive
Officer and President
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
Press
release issued by MusclePharm Corporation, dated August 14, 2018,
announcing financial results.
|